Castle Biosciences CSTL
NASDAQ CSTL
$33.08 -0.11 (-0.33%)
At close: Oct 23, 2026 · 4:00 PM EDT

Castle Biosciences (CSTL) Cost of Revenue (2018 - 2026)

Updated

Castle Biosciences' Cost of Revenue was $23.7 million in Q2 2026, up 34.5% from $17.63 million a year earlier and up 15.4% from the prior quarter.

Analysis

Castle Biosciences (CSTL) Cost of Revenue (2018 - 2026) Analysis & Trends

On a trailing twelve-month basis, Castle Biosciences' Cost of Revenue was $81.25 million through Jun 30, 2026, up 23.5% year-over-year; for FY2025, it was $71.03 million, up 18.0% from FY2024.

  • Cost of Revenue has now increased for seven consecutive years, with a five-year compound annual growth rate of 49.0% (FY2020 to FY2025).
  • In earlier years, Cost of Revenue was $60.21 million in FY2024 (+33.8%), $44.98 million in FY2023 (+40.5%), $32.01 million in FY2022 (+102.3%) and $15.82 million in FY2021 (+63.4%).
  • The Q2 2026 figure marks the highest quarterly Cost of Revenue in data going back to Q2 2018.
  • Compared with a year earlier, Cost of Revenue has increased for 29 straight quarters, with growth averaging 25.0% over the last eight quarters.
  • The year-over-year growth in Cost of Revenue has ranged between 13.2% (Q4 2025) and 107.9% (Q2 2022) over the last five years.
  • Per Business Quant data, CSTL's Cost of Revenue in the three quarters before Q2 2026 was $20.53 million (Q1 2026), $18.32 million (Q4 2025) and $18.7 million (Q3 2025).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
API Access

Castle Biosciences Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=CSTL&period=max&api_key=YOUR_API_KEY